» Articles » PMID: 35265060

Polycationic Glycopolymer Demonstrates Activity Against Persisters and Biofilms of Non-tuberculosis Cystic Fibrosis Clinical Isolates

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2022 Mar 10
PMID 35265060
Authors
Affiliations
Soon will be listed here.
Abstract

Non-tuberculosis (NTM) is a group of opportunistic pathogens associated with pulmonary infections that are difficult to diagnose and treat. Standard treatment typically consists of prolonged combination antibiotic therapy. Antibiotic resistance and the role of biofilms in pathogen communities, such as NTM persister cells, is an important unmet challenge that leads to increased toxicity, frequent relapse, poor clinical management, and an extended treatment period. Infection recurrence and relapse are not uncommon among individuals with cystic fibrosis () or chronic obstructive pulmonary disease (COPD), where thick mucus supports bacterial biofilm production and impairs mucociliary clearance. The study evaluates a membrane-active cationic glycopolymer [poly (acetyl, arginyl) glucosamine (PAAG)] being developed to support the safe and effective treatment of NTM biofilm infections. PAAG shows antibacterial activity against a wide range of pathogenic bacteria at concentrations non-toxic to human epithelial cells. Time-kill curves demonstrated PAAG's rapid bactericidal potential at concentrations as low as 1X MIC against all NTM strains tested and compared to the standard of care. PAAG treatment prevents persister formation and eradicates antibiotic-induced persister cells in planktonic NTM cultures below the limit of detection (10 colony-forming unit (CFU)/ml). Further, PAAG showed the ability to penetrate and disperse NTM biofilms formed by both rapidly and slowly growing strains, significantly reducing the biofilm biomass ( < 0.0001) compared to the untreated NTM biofilms. Microscopical examination confirmed PAAG's ability to disrupt and disperse mycobacterial biofilms. A single PAAG treatment resulted in up to a 25-fold reduction in live-labeled NTM and a 78% reduction in biofilm thickness. Similar to other polycationic molecules, PAAG's bactericidal and antibiofilm activities employ rapid permeabilization of the outer membrane of the NTM strains, and subsequently, reduce the membrane potential even at concentrations as low as 50 μg/ml ( < 0.001). The outcomes of these analyses suggest the importance of this polycationic glycopolymer, PAAG, as a potential therapeutic agent for opportunistic NTM infections.

Citing Articles

Fate of cultured populations when exposed to moxifloxacin.

Salina E, Martini B, Sorokin V, Mulyukin A Front Microbiol. 2024; 15:1494147.

PMID: 39669783 PMC: 11635960. DOI: 10.3389/fmicb.2024.1494147.


Bacterial persisters: molecular mechanisms and therapeutic development.

Niu H, Gu J, Zhang Y Signal Transduct Target Ther. 2024; 9(1):174.

PMID: 39013893 PMC: 11252167. DOI: 10.1038/s41392-024-01866-5.


Molecular mechanism analysis of nontuberculous mycobacteria infection in patients with cystic fibrosis.

Chen Q, Li J Future Microbiol. 2024; 19(10):877-888.

PMID: 38700285 PMC: 11290754. DOI: 10.2217/fmb-2023-0237.


Nontuberculous Mycobacteria, Mucociliary Clearance, and Bronchiectasis.

Retuerto-Guerrero M, Lopez-Medrano R, de Freitas-Gonzalez E, Rivero-Lezcano O Microorganisms. 2024; 12(4).

PMID: 38674609 PMC: 11052484. DOI: 10.3390/microorganisms12040665.


A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.

Kaur P, Krishnamurthy R, Shandil R, Mohan R, Narayanan S Pathogens. 2024; 13(1).

PMID: 38251347 PMC: 10819454. DOI: 10.3390/pathogens13010040.


References
1.
Gollan B, Grabe G, Michaux C, Helaine S . Bacterial Persisters and Infection: Past, Present, and Progressing. Annu Rev Microbiol. 2019; 73:359-385. DOI: 10.1146/annurev-micro-020518-115650. View

2.
Mukherjee D, Zou H, Liu S, Beuerman R, Dick T . Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development. Future Microbiol. 2016; 11:643-50. DOI: 10.2217/fmb-2015-0015. View

3.
Garcia B, McDaniel M, Loughran A, Johns J, Narayanaswamy V, Fernandez Petty C . Poly (acetyl, arginyl) glucosamine disrupts biofilms and enhances bacterial clearance in a rat lung infection model. Microbiology (Reading). 2022; 168(1). PMC: 8914243. DOI: 10.1099/mic.0.001121. View

4.
Fisher R, Gollan B, Helaine S . Persistent bacterial infections and persister cells. Nat Rev Microbiol. 2017; 15(8):453-464. DOI: 10.1038/nrmicro.2017.42. View

5.
Griffith D, Eagle G, Thomson R, Aksamit T, Hasegawa N, Morimoto K . Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018; 198(12):1559-1569. DOI: 10.1164/rccm.201807-1318OC. View